Welcome to our dedicated page for Afya news (Ticker: AFYA), a resource for investors and traders seeking the latest updates and insights on Afya stock.
Afya Limited reports financial, regulatory and capital-allocation developments for a Brazil-based medical education group and medical practice solutions provider. The company serves medical students and physicians through an end-to-end ecosystem that includes undergraduate medical education, residency preparation, continuing medical education, graduate programs and practice-management solutions.
Recurring company developments include IFRS financial results in Brazilian reais, medical-seat authorizations from Brazil’s Ministry of Education, campus-level capacity changes, credit-rating actions, dividends, share repurchases and board changes. Afya also reports activity in continuing education, B2B revenue, clinical management tools and the broader physician base that uses its education and medical practice platforms.
Afya (Nasdaq: AFYA) reported 1Q26 results: revenue R$1,012.7M (+8.2% YoY), Adjusted EBITDA R$511.4M (+4.0% YoY) and Adjusted EBITDA margin 50.5% (‑200 bps YoY). Net income was R$261.8M and basic EPS was R$2.88 (+3.0%). Free cash flow was R$376.0M and cash was R$1,332.9M. Ecosystem reached ~303.6k users and approved medical seats totaled 3,768. Moody’s reaffirmed AAA.br with stable outlook. 2026 guidance: Revenue R$3,950–4,100M; Adjusted EBITDA R$1,700–1,800M; CAPEX R$340–380M.
Afya (Nasdaq: AFYA) announced that Moody's reaffirmed its AAA.br credit rating on May 6, 2026, with a stable outlook. The rating reflects revenue growth, above-industry margins, very strong credit metrics, exceptional cash generation, robust liquidity, a strong competitive position, and prudent financial policy.
Afya highlighted proactive liability management, disciplined capital allocation and an appetite for M&A as part of its credit profile.
Afya (Nasdaq: AFYA) reported strong 4Q25 and FY25 results: FY25 revenue R$3,697.3m (+11.9% YoY), Adjusted EBITDA R$1,680.3m (+15.4% YoY) and Free Cash Flow R$1,056m. 4Q25 revenue was R$913.0m (+7.5% YoY) and adjusted EBITDA margin was 45.4% for FY25. The Board approved a R$307.4m dividend and a share buyback program of up to 4,000,000 Class A shares.
Management delivered 2025 guidance, reported solid cash of R$1,125.4m, and issued 2026 guidance: revenue R$3,950–4,100m and Adjusted EBITDA R$1,700–1,800m.
Afya (Nasdaq: AFYA) announced a cash dividend distribution of R$307.4 million, equal to R$3.446838 per share, approved on March 12, 2026 and payable in U.S. dollars on April 6, 2026 to shareholders of record as of March 25, 2025.
The dividend represents 40% of consolidated net income for 2025; combined with ongoing buybacks the company expects to distribute 50% of 2025 consolidated net income. Payment will use the PTAX exchange rate published March 13, 2026.
Afya (Nasdaq: AFYA) announced that Brazil's Ministry of Education regulator (MEC) authorized an increase of 63 medical seats for ITPAC Afya Abaetetuba, raising that campus capacity to 113 seats. Afya Cametá remains non-operational, which enabled reallocation of capacity. Across its portfolio, Afya now has 3,766 approved medical seats. The authorization reinforces Afya's expansion of medical training capacity in the Pará health region and its position as a leading medical education provider in Brazil.
Afya (Nasdaq: AFYA) announced that Maria Tereza Azevedo notified the company of her intent to resign from the Board of Directors effective December 31, 2025.
The release restates the Board composition, which includes two co-chairmen (one representing Bertelsmann and one representing the Esteves family), additional members from those shareholders, and four independent directors, highlighting a mix of shareholder representatives and independent directors.
Board members listed include Nicolau Carvalho Esteves, Kay Krafft, Benedikt Dalkmann, Christina Krebs, Renato Tavares Esteves, João Paulo Seibel de Faria, Vanessa Claro Lopes, Miguel Filisbino Pereira de Paula, and Marcelo Ken Suhara.
Afya (Nasdaq: AFYA) reported strong 3Q25 and 9M25 results with 3Q25 revenue R$928.5m (+10.4% YoY) and 3Q25 adjusted EBITDA R$398.9m (+14.6% YoY) producing a 3Q25 adjusted EBITDA margin of 43.0% (+160 bps). Nine months revenue reached R$2,784.3m (+13.4% YoY) and 9M25 adjusted EBITDA was R$1,291.7m (+18.5% YoY) with a 46.4% margin (+200 bps). Operating cash conversion was 101.5% and cash balance was R$996.8m. The company reaffirmed full‑year 2025 guidance: revenue R$3,670–3,770m, adjusted EBITDA R$1,620–1,720m, and CAPEX R$250–290m. Subsequent actions included a R$1.5bn commercial notes issuance, repurchase and cancellation of 150,000 Series A preferred shares, and a new share buyback program up to 4m Class A shares.
Afya (Nasdaq: AFYA) announced that Brazil's Ministry of Education regulator authorized an increase of 100 medical seats at ITPAC Porto Nacional — AFYA Faculdade de Ciências Médicas Bragança in Bragança, Pará.
With the authorization, the Bragança campus now has 150 medical seats, and Afya's total approved medical seats reach 3,753. The company highlighted this expansion as evidence of its continued role in medical education in Brazil.
Afya (Nasdaq: AFYA) agreed to repurchase all 150,000 Series A perpetual convertible preferred shares from an affiliate of Softbank for an aggregate purchase price of R$831.6 million, with the transaction expected to close on November 3, 2025. The company intends to cancel the Series A preferred shares upon completion.
Afya also repaid in full R$500.0 million of debentures issued by subsidiary Afya Participações on October 22, 2025; those debentures had been issued on December 16, 2022 with maturities in January 2027 and January 2028. Both actions are funded with proceeds from Afya Brazil commercial notes issued on October 15, 2025.
Afya (Nasdaq: AFYA) announced that Afya Participações S.A. approved a private placement of book-entry commercial notes totaling R$1,500.0 million in two series to be sold to Opea and securitized via a debenture.
The issuance is intended for October 15, 2025; the First Series is R$500.0 million maturing Oct 15, 2028 and the Second Series is R$1,000.0 million maturing Oct 15, 2030. Interest equals the Brazilian daily interbank deposit rate (DI) plus spreads of 0.70% (First Series) and 0.85% (Second Series) per year. Notes will be guaranteed by three subsidiaries. Proceeds are for general corporate purposes, including optional early debenture redemption and repurchase of perpetual convertible preferred shares.